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cer-specific quality of life dimension scores are signifi-
cantly related to EuroQol-5D scores.
CARDIOVASCULAR DISEASE
PCV1
COST-EFFECTIVENESS OF LIPID MODULATOR 
AGENTS
LeLorier J, Lacour A, Derderian F
Centre de recherche, Centre hospitalier de l’Université de 
Montréal, Campus Hôtel-Dieu, Québec, Canada
OBJECTIVE: In an era of cost-conscientiousness and
budgetary restraints, the cost-effectiveness of lipid modu-
lator agents must be considered. The study objective was
to evaluate the cost-effectiveness ratio of lipid modulator
agents, based on the agent’s effects on total cholesterol/
HDL-cholesterol ratio (TC/HDL-c) and on the cost of ac-
quisition.
METHODS: The choice of TC/HDL-c for the efficacy
criterion was dictated by the overwhelming evidence that
it is the most predictive parameter in assessing CHD risk
when compared to other lipid/lipoprotein levels or ratios.
Also, the evidence supporting the crucial role played by
HDL is demonstrated in several studies, among which are
the Framingham Study, LRC-CPPT, MRFIT, and PRO-
CAM. The cost of acquisition of each medication was ob-
tained from the Quebec Provincial Formulary (Liste de
Medicament—July 1996). The meta-analysis of each dose
of each medication’s effects on TC/HDL was based on a
search generating 456 publications, from which 124 met
the appropriate criteria. 
RESULTS: From these publications, on average, the pop-
ulation is 50.5 years old, with 62.5% males; the baseline
TC/HDL is 7.3. The various doses of each medication
were ranked into three categories of efficacy based on the
percent decrease of the TC/HDL ratio: less than 20%,
20–30%, and greater than 30%.
CONCLUSION: In the most effective category, the medi-
cations which showed the best efficacy to cost ratio were
fluvastatin 60 mg (20% decrease per $ per day) and mi-
cronized fenofibrate 200 mg (19% decrease per $ per
day), and then simvastatin 20 mg (15% decrease per $
per day).
PCV2
ADAPTING ECONOMIC ANALYSES FROM ONE 
COUNTRY TO ANOTHER: DO THE WOSCOPS 
UK FINDINGS HOLD IN BELGIUM?
Huybrechts KF, Caro JJ
The WOSCOPS Study Group, Caro Research, Boston, MA, US
In a previous analysis, based on the West of Scotland
Coronary Prevention Study (WOSCOPS), pravastatin
was demonstrated to lower the risk of cardiovascular dis-
ease (CVD) in hypercholesterolemic men, at an economic
efficiency that is not prohibitive overall from the perspec-
tive of the National Health Service in the UK. For these
results to provide guidance to those who set policy in
other jurisdictions, they must account for differences
among healthcare systems.
OBJECTIVE: The applicability of these findings to the
Belgian setting was investigated by integrating the
WOSCOPS results and Belgian epidemiological, resource
use, and cost data.
METHODS: The Belgian Interuniversity Research on
Nutrition and Health data were used to evaluate the
baseline risk factor distribution and to partially validate
the CVD exponential regression model derived from
WOSCOPS. The rates at which subjects move for the first
time from health to CVD were calculated, assuming the
relative efficacy for pravastatin observed in WOSCOPS.
The number of such transitions avoided was valued in
terms of cost savings to the Belgian healthcare system and
life-years gained. Resource use and costs were primarily
derived from diagnosis-related expenditure in a subset of
Belgian hospitals. Belgian life table data were obtained
and substituted for the Scottish data to account for differ-
ences in life expectancy.
RESULTS: The cost-effectiveness ratio remains well be-
low USD 25,000 (BEF 37  USD 1) per life-year gained,
the bound typically considered as “moderate to strong
evidence for adoption and appropriate utilization.”
CONCLUSION: Although the precise estimate depends
on the specifics of the country, the variation does not
have an impact on the treatment decision the initial study
supports.
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EFFICACY OF CARDIAC REHABILITATION 
THERAPY: A PROSPECTIVE MULTICENTER 
COHORT STUDY
Willich SN, Völler H, Binting S, Gohlke H, Hahmann H, 
Kleber F, Klein G, Krobot K, Bestehorn K
The PIN Study Group, Institute for Social Medicine and 
Epidemiology, Charité University Hospital, Humboldt University 
of Berlin, Berlin, Germany
To determine the efficacy of cardiac inpatient rehabilita-
tion therapy (RT), 2442 consecutive patients (78% male,
age 60 (10 years), and 22% female, age 65 (10
years) in 18 rehabilitation centers were examined in the
period from January to June 1997. The primary indica-
tions for RT were myocardial infarction (56%), PTCA
(6%), and CABG (38%). RT was initiated 34 days (me-
dian) after the acute event. During hospitalization (26 
5 days), patients received standard health training and
medical therapy. Diagnostic tests and standardized sur-
veys were prospectively documented. The prevalence of
conventionally defined cardiovascular risk factors at the
start and end of the rehabilitation therapy is shown in the
table below.
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Subjective well-being (v. Zerssen scale) improved during
RT from 15.7  8 to 11.8  8 (p  0.001).
CONCLUSION: Alterable cardiovascular risk factors
and subjective quality of life are significantly improved
by health training and treatment during standardized car-
diac inpatient rehabilitation therapy. Follow-up studies
are needed to assess the long-term course and to improve
preventive strategies.
PCV4
THE ECONOMIC IMPACT OF HYPERTENSION 
STUDY FROM THE PISTOIA PROJECT
Potenza A1, Berto P2, Feroci P1, Lattari P1, Pacini R1, Mundula 
V1, Papini D3, Reggio S4
1ASL 3, Pistoia, Italy; 2Pbe consultants, Verona, Italy; 3School of 
Medicine, Firenze, Italy; 4Pfizer Italiana, Roma, Italy
OBJECTIVE: Within the Pistoia Project (PP), a large
screening study whose objective is the identification of
hypertensive disease, organ damage, and related risk fac-
tors to activate actions of primary and secondary preven-
tion, we conducted a preliminary cost of illness analysis
to investigate if age, gender, and/or severity of hyperten-
sion could influence the use of healthcare services and
therefore have a direct impact on costs.
METHODS: Forty-five patients’ records were randomly
selected from the GP’s screening forms of the PP: patients
were either hypertensive or normotensive under treat-
ment. Using healthcare codes, we computed hospital data
(DRG code and cost), while pharmaceutical consumption
(units and cost) was retrieved from the pharmaceutical re-
gional database. The local Hypertension Centre retrieved
number and typology of specialist consultations and pro-
cedures. Indirect costs were partly calculated from social
security system certificates, and partly estimated under
the hypothesis that each hospital stay and each specialist
visits imply a loss of working days.
RESULTS: In 1997, 45 patients generated a total cost of
Lit. 29.9 million, with an average cost per patient per
year of Lit. 664,282. Pharmaceutical care accounted for
45% of total cost, followed by hospital admissions
(34%), productivity losses (16.4%), and specialist visits
and procedures (4.3%). 
CONCLUSIONS: This preliminary analysis has demon-
strated the potential of such an instrument to evaluate the
cost of managing hypertension in a large area as the Pis-
toia province. Further research is needed on larger sam-
ples to identify patterns of resource use and to evaluate
the influence of illness severity on the total cost of this
disease.
PCV5
POTENTIAL COST SAVINGS OF THE 4 FRENCH 
INFINITI CATHETER IN DIAGNOSTIC 
CORONARY ANGIOGRAPHY
Neighbors D1, Buckingham T1, Greiner W2, Schulenburg J2
1Center for Economics Research, Research Triangle Institute, 
Research Triangle Park, NC, US; 2Centre for Health Economics 
and Health System Research, University of Hannover, 
Hannover, Germany
OBJECTIVE: To estimate the economic value of the 4F
catheter relative to the 6F in diagnostic coronary angiog-
raphy.
METHODS: A decision tree model was developed, based
on German practice patterns and costs. Expected total
costs of diagnostic coronary angiography using 4F and 6F
catheters in both the ambulatory and inpatient settings
were calculated and compared, together with measures of
procedure success. Costs include the costs of catheters,
contrast media, time in clinic, professional services, and
costs to treat complications. Measures of procedure suc-
cess, as observed in trials of 4F versus 6F, include fluoros-
copy, procedure, compression, and immobilization times;
complication rates; and catheter exchange rates. Complica-
tion rates are those observed in two large German observa-
tional studies. 
RESULTS: In the base-case scenario, the 4F catheter
saves an average of 22 DM per procedure, despite a
higher list price. These savings derive primarily from re-
duced need for contrast media. The 4F is associated with
fewer complications; however, because of the low overall
complication rate, the associated savings are minor.
Given a lower likelihood of bleeding complications, the
4F may enable more procedures to be performed in the
ambulatory setting. Assuming a modest increase in the
proportion of ambulatory procedures results in an addi-
tional savings of 10 DM per procedure.
CONCLUSION: Compared to the 6F catheter, the 4F is
estimated to save an average of 22 DM per diagnostic
coronary angiography because of a reduced need for con-
trast media and a lower complication rate. If the 4F cath-
eter enables more procedures to be performed on an out-
patient basis, the potential cost savings increase.
PCV6
MEASURING DISEASE-SPECIFIC SYMPTOM 
IMPACT: DEVELOPMENT OF THE ATRIAL 
FIBRILLATION IMPACT SCALE (AFIS)
Turner R, Kocal M, Testa M
PHASE V Technologies Inc, Wellesley Hills, MA, US; Harvard 
School of Public Health, Boston, MA, US
Admission (%) Discharge (%)
Arterial BP 140/90 mmHg 24 ** 8
Smoking 39 ** 5
Cholesterol 250 mg/dl 20 ** 5
LDL cholesterol 100 mg/dl 87 ** 67
LDL/HDL cholesterol 2.5 86 ** 70
Triglycerides 200 mg/dl 22 * 15
Glucose 140 mg/dl 14 ns 11
BMI 30 kg/m2 18 * 15
* p  0.01, ** p  0.001, ns  not significant.
